Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
TERPS Trial for de Novo Oligometastic Prostate Cancer
NCT05223803 · View on ClinicalTrials.gov ↗
Study Summary
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
Conditions Studied
Interventions
- RADIATION Prostate radiation (XRT)
- DRUG Systemic Therapy
- RADIATION Stereotactic ablative radiation therapy (SABR)
Study Locations (9)
Maryland
- Maryland Proton Treatment Center — Baltimore
- UMMC — Baltimore
- Upper Chesapeake Health — Bel Air
- Central Maryland Radiation Oncology — Columbia
- Baltimore Washington Medical Center — Glen Burnie
Pennsylvania
- Sidney Kimmel Cancer Center at Jefferson Health — Philadelphia
- UPMC Hillman Cancer Center — Pittsburgh
California
- UC San Diego Moores Cancer Center — La Jolla
Virginia
- Bon Secours Cancer Institute at St. Francis — Midlothian
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2022-10-18 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05223803
The ClinicalTrials.gov registry entry for NCT05223803 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 559 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions — of which Prostate radiation (XRT) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05223803 reports 9 study locations spanning 4 distinct geographic areas — top geographies include Maryland, Pennsylvania, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05223803 about?
NCT05223803 is a clinical study titled "TERPS Trial for de Novo Oligometastic Prostate Cancer". This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
What is the current status of trial NCT05223803?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2022-10-18. Estimated completion is 2027-07-31.
What conditions does trial NCT05223803 study?
This clinical trial studies the following conditions: Prostate Cancer, Oligometastatic Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05223803?
The interventions under investigation include: Prostate radiation (XRT) (RADIATION), Systemic Therapy (DRUG), Stereotactic ablative radiation therapy (SABR) (RADIATION). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05223803?
This trial is sponsored by University of Maryland, Baltimore, which has 559 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05223803 being conducted?
This trial has 9 study locations across California, Maryland, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.